InvestorsHub on MSN
ImmunityBio shares jump after Saudi approval of ANKTIVA for lung cancer
Shares of ImmunityBio (NASDAQ:IBRX) climbed 6% on Wednesday morning after the company said Saudi Arabia’s Food and Drug ...
If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
Health and Me on MSN
Lung cancer symptoms can show up on your fingers: Here’s what to look for
Lung cancer can show early signs beyond a persistent cough or breathlessness. Learn about symptoms that may appear on your ...
Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...
Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...
Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...
A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback